Liver fibrosis is characterized by the activation and migration of hepatic stellate cells (HSCs), followed by matrix deposition. Recently, several studies have shown the importance of extracellular vesicles (EVs) derived from liver cells, such as hepatocytes and endothelial cells, in liver pathobiology. While most of the studies describe how liver cells modulate HSC behavior, an important gap exists in the understanding of HSC-derived signals and more specifically HSC-derived EVs in liver fibrosis. Here, we investigated the molecules released through HSC-derived EVs, the mechanism of their release, and the role of these EVs in fibrosis. Mass spectrometric analysis showed that platelet-derived growth factor (PDGF) receptor-alpha (PDGFRa) was enriched in EVs derived from PDGF-BB-treated HSCs. Moreover, patients with liver fibrosis had increased PDGFRa levels in serum EVs compared to healthy individuals. Mechanistically, in vitro tyrosine720-to-phenylalanine mutation on the PDGFRa sequence abolished enrichment of PDGFRa in EVs and redirected the receptor toward degradation. Congruently, the inhibition of Src homology 2 domain tyrosine phosphatase 2, the regulatory binding partner of phosphorylated tyrosine720, also inhibited PDGFRa enrichment in EVs. EVs derived from PDGFRa-overexpressing cells promoted in vitro HSC migration and in vivo liver fibrosis. Finally, administration of Src homology 2 domain tyrosine phosphatase 2inhibitor, SHP099, to carbon tetrachloride-administered mice inhibited PDGFRa enrichment in serum EVs and reduced liver fibrosis. Conclusion: PDGFRa is enriched in EVs derived from PDGF-BB-treated HSCs in an Src homology 2 domain tyrosine phosphatase 2-dependent manner and these PDGFRa-enriched EVs participate in development of liver fibrosis. (HEPATOLOGY 2018;68:333-348).
D
espite the great potential of the liver to regenerate, some injurious stimuli, such as chronic alcohol exposure or hepatitis C virus infection, can lead to liver fibrosis, followed by liver cirrhosis. (1) Cirrhosis is a significant cause of mortality, representing 2% of worldwide total deaths in 2010. (2) Therefore, there is an urgent need to develop effective therapies. The development of tyrosine kinase inhibitors and, in Abbreviations: ALD, alcoholic liver disease; Atg5, autophagy-related 5; BDL, bile duct ligation; C459S, cysteine459-to-serine; Erk1/2, extracellular signal-regulated kinase 1/2; EV, extracellular vesicle; GFP, green fluorescent protein; HA, hemagglutinin; HSC, hepatic stellate cell; LPS, lipopolysaccharide; NTA, nanoparticle-tracking analysis; p62, sequestosome-1; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; RTK, receptor tyrosine kinase; SHP2, Src homology 2 domain tyrosine phosphatase 2; siRNA, small interfering RNA; aSMA, alpha smooth muscle actin; TGFb, transforming growth factor beta; WB, western blot; WT, wild-type; Y720E, tyrosine720-to-glutamate; Y720F, tyrosine720-to-phenylalanine. particular, platelet-derived growth factor (PDGF) receptor (PDGFR) inhibitors, for the treatment of liver fibrosis represents an active area of investigation. (3) Thus, a better understanding of the molecular and cellular mechanisms regulating liver fibrosis may facilitate the identification of novel therapeutic strategies.
Liver fibrosis is characterized by the activation, migration, and proliferation of quiescent liver pericytes, called hepatic stellate cells (HSCs), with subsequent fibrogenesis. Key pathways that contribute to liver fibrosis are PDGF-BB, transforming growth factor b (TGFb), vascular endothelial growth factor, connective tissue growth factor, and reactive oxygen species secreted by several cell types, such as hepatocytes, Kupffer cells, endothelial cells, profibrotic macrophages, biliary epithelial cells, and platelets. (4) (5) (6) (7) PDGF-BB binds to PDGFRs and induces receptor autophosphorylation on specific tyrosine residues. (8) While PDGFRb is well studied, less is known about PDGFRa.
(1) Ligand binding to PDGFRa induces phosphorylation of several tyrosines such as Y572, Y574, (9) and Y720. (10) Molecules such as Src homology 2 domain tyrosine phosphatase 2 (SHP2) can bind to these specific phosphorylated tyrosines of the receptor for downstream signaling activation, leading to HSC proliferation and migration. (1) Interestingly, Hayes et al. reported that in vivo genetic deletion of PDGFRa reduced liver fibrosis. (11) Nevertheless, there exists a lack of studies regarding the mechanism and role of PDGFRa in liver fibrosis.
Extracellular vesicles (EVs) have been shown to play an important role in liver diseases. (12) (13) (14) EVs are cellderived, nano-sized vesicles secreted in the extracellular milieu. They can originate from cell membrane budding or from multivesicular body content release. (13) In liver, our group and others have demonstrated that cellular stress enhances hepatocyte EV secretion and modifies EV cargo. (12, (15) (16) (17) (18) Lipotoxicity-induced EV release from hepatocytes recruits proinflammatory macrophages, (12) which secrete cytokines and chemokines such as PDGFs and TGFb inducing HSC activation. (7) Furthermore, sphingosine kinase 1-enriched EVs derived from sinusoidal endothelial cells induce HSC migration in a sphingosine 1 phosphate-dependent manner. (19) While most of the studies describe how liver cells modulate HSC behavior, an important gap exists in the understanding of HSC-derived signals and more specifically HSC-derived EVs in liver fibrosis.
In this study, we demonstrate that PDGFRaenriched, HSC-derived EVs promoted liver fibrosis. This enrichment was due to the specific phosphorylation of tyrosine 720 (Y720) in the intracellular kinase domain of the receptor. Phosphorylated Y720 recruited SHP2, which accompanied PDGFRa to the EVs. PDGFRa-enriched EVs induced in vitro HSC migration by triggering downstream motility signaling in the recipient cells. In vivo transplantation of PDGFRaenriched EVs promoted liver fibrosis. Finally, in vivo inhibition of SHP2 blocked PDGFRa enrichment in serum EVs and liver fibrosis. These results suggest that the targeting of PDGFRa in HSC-derived EVs is a mechanism to regulate PDGFRa cellular levels upon ligand binding and to promote liver fibrosis.
Materials and Methods

EV PURIFICATION
EVs were purified from cell conditioned media, mouse serum, or human serum by differential ultracentrifugation (20) : 10 minutes at 300g, 30 minutes at 20,000g (20k fraction), and 2.5 hours at 110,000g (110k fraction) using the OptimaXPN-80 ultracentrifuge. EVs were resuspended at the same volume for nanoparticle-tracking analysis (NTA; NS300) or western blot (WB) analysis.
(BDL) to induce liver fibrosis, as described, (21) and were kept for 3 weeks. In a second model of liver fibrosis, CCl 4 (1 lL/g; Sigma-Aldrich; no. 319961) was administered twice a week for 4 weeks. SHP099 (MedChemExpress; HY-100388) was dissolved in 5% dimethyl sulfoxide and administered daily at 5 mg/kg for 4 weeks. For EV transplant, unlabeled or PKH76-labeled PDGFRa-overexpressing LX2-derived EVs were used; 2 3 10 9 EVs/mouse/day (22) were administered daily for 3-4 weeks. Serum and livers were analyzed by sirius red, Masson's trichrome, and WB. Serum EVs derived from olive oil-treated, CCl 4 -treated, or CCl 4 1SHP099-treated mice were administrated daily at 100 lg of EVs/ mouse/day to WT mice for 10 days. CCl 4 , SHP099, and EVs were administered intraperitoneally. Protocols for in vivo experiments were approved by the Mayo Clinic IACUC Committee.
PATIENT SAMPLES
Patient serum samples were obtained and analyzed under Mayo Clinic institutional review boardapproved protocols. Patient demographics are detailed in Table 1 .
STATISTICAL ANALYSIS
All experiments were done at least in triplicate, from three independent experiments. The data were analyzed using analysis of variance with Bonferroni posttest and t tests. For in vitro results, a paired t test was used. The difference was considered significant when P < 0.05. The results are presented as mean 6 SEM.
The Supporting Information describes cell culture, EV imaging, mass spectrometry, WB, primary antibodies, gene expression, small interfering RNA (siRNA) knockdown, site-directed mutagenesis, mutagenesis primers, wound-healing assay, phospho-kinase assay, and immunofluorescence.
Results
PDGFRa IS ENRICHED IN HSC-DERIVED EVs
As a first step for our study, we collected primary human HSC-derived EVs by differential ultracentrifugation (Fig. 1A, left) . WB showed that the 110k EVs expressed high levels of tumor susceptibility gene 101 and cluster of differentiation 81, which are reported to be enriched in exosomes compared to microvesicles, (23) but not transferrin receptor, when compared to wholecell lysate and the 20k pellet. Moreover, 110k EVs were negative for the endoplasmic reticulum molecule calnexin, confirming the purity of these EVs and the absence of cell debris (Fig. 1A, middle) . NTA showed that 110k EV mode size was approximately 110 nm (Fig. 1A, right) . Due to a size overlap between exosomes and microvesicles, the 110k fraction might contain some subsets of smaller microvesicles as well as exosomes. Next, HSCs were treated with vehicle, TGFb, or PDGF-BB for 12 hours to induce HSC activation. Compared to vehicle, PDGF-BB, but not TGFb, treatment increased EV release by more than 50% with no significant change in EV size as assessed by NTA (Supporting Fig. S1A ). This increase in EV release was confirmed by WB when loading the same volume of media for each condition (Supporting Fig. S1B) .
To examine the effect of PDGF-BB on the protein cargo released through HSC-derived EVs, we performed an unbiased mass spectrometry-based analysis using the same number of EVs per condition. A total of 2,364 proteins were detected (Supporting Table  S1 ), 440 of which were at least 2-fold up-regulated in the PDGF-BB condition (Fig. 1B, pie chart) . A filter of at least 10 weighted spectrum counts per protein and at least 80% exclusivity (Supporting Table S1 ) brought the number of proteins to 56 (Fig. 1B, pie  chart) . These 56 up-regulated proteins were examined using gene ontology enrichment analysis to identify Fig. 1B, histogram) , which is one feature of liver fibrosis. PDGFRa, a receptor tyrosine kinase (RTK) involved in cell migration, was common to these processes and enriched under the PDGF-BB condition; PDGFRb showed no difference between the conditions (Supporting Table S1 ). At the mRNA level, PDGFRa did not show enrichment in EVs (Supporting Fig. S2A ,B), suggesting that the enrichment is not due to increased transcription but to packaging of the protein into the EVs. Additionally, TGFb treatment did not affect PDGFRa enrichment in EVs (Supporting Table S1 ). PDGFRa enrichment after PDGF-BB, but not TGFb or PDGF-AA, treatment was confirmed by immunogold-coupled transmission electron microscopy and WB ( Fig. 1C ; Supporting Figs. S1B and S2C-E). Furthermore, PDGFRa was enriched in serum EVs from alcoholic liver disease (ALD) patients and from mice after chronic liver injury induced by BDL (Fig. 1D ). In BDL mouse liver, PDGFRa is mainly expressed by alpha-smooth muscle actin-positive (aSMA 1 ) cells (Fig. 1E ), suggesting that PDGFRa-enriched EVs from the liver derive principally from activated HSCs. However, PDGFRa enrichment was not observed in primary sclerosing cholangitis patient sera when compared to control (Supporting Fig. S2F ), suggesting that the mechanism of PDGFRa targeting to EVs might be different in primary sclerosis cholangitis patients compared to ALD patients. Taken together, these results demonstrate that HSCs release PDGFRa-enriched EVs. Moreover, ALD patients and mice with liver fibrosis show an increase in PDGFRa enrichment in their serum EVs.
INHIBITION OF DEGRADATION LEADS TO ENHANCED PDGFRa ENRICHMENT IN EVs
PDGFRa is an RTK that upon ligand binding is internalized into the endosomes and degraded. (24) (25) (26) Nevertheless, our results demonstrate that PDGFRa can also be released through EVs. Therefore, we sought to investigate whether impaired degradation affects PDGFRa enrichment in EVs. One hour prior to PDGF-BB addition, HSCs were pretreated with MG132, E64d, or bafilomycin A1 to block proteasome, lysosome, or autophagic degradation, respectively. MG132 and bafilomycin A1, but not E64d, induced PDGFRa enrichment in EVs. MG132 enhanced PDGFRa enrichment by 2-fold compared to the PDGF-BB condition but significantly reduced PDGFRa cellular levels ( Fig. 2A) . Bafilomycin A1 induced a significant 3-fold increase of PDGFRa enrichment in EVs and a massive accumulation of PDGFRa in cell lysates when compared to PDGF-BB only ( Fig. 2A ), which suggests a decrease of PDGFRa degradation. None of the treatments significantly affected PDGFRa mRNA levels (Fig. 2B ). Microtubule-associated protein 1 light chain 3 beta and sequestosome-1 (p62) up-regulation after bafilomycin A1 treatment also suggested a role for autophagic degradation in PDGFRa release through EVs. Similar results were obtained when treating PDGFRaexpressing LX2 cells (HSC line) but not when treating primary human hepatocytes, where degradation inhibition did not induce PDGFRa enrichment in hepatocyte-derived EVs, indicating HSC selectivity for this effect (Fig. 2C ). To confirm that inhibition of PDGFRa degradation enriches the receptor in the EVs, we blocked autophagy by silencing autophagyrelated 5 (Atg5), one of the autophagosome
FIG. 1. PDGFRa is enriched in HSC-derived EVs. (A)
The differential ultracentrifugation method was used for EV purification (left). HSC whole-cell lysate, HSC-derived EVs (20k and 110k), and EV-depleted media were analyzed by WB (middle). The 110k EVs were analyzed by NTA (right). (B) Mass spectrometry on EVs derived from 12 hour-treated HSCs with vehicle or PDGF-BB. Out of 2,364 detected proteins, 440 were at least 2-fold up-regulated. A filter of at least 10 weighted spectrum counts per protein and at least 80% of exclusivity were applied to the 440 molecules, giving a total number of 56 proteins. Gene ontology analysis of the 56 proteins implicated them in several biological processes (P < 0.05). In red are the processes implicated in cell migration. PDGFRa, its binding partner SHP2, and its ligand PDGF-BB were common to these processes. components. Atg5 knockdown was confirmed by WB (Fig. 2D ). Atg5 siRNA transfection followed by 12-hour PDGF-BB treatment induced a significant increase of PDGFRa enrichment in EVs (Fig. 2E) without affecting PDGFRa gene expression (Fig. 2F ), similarly to bafilomycin A1. In summary, these results demonstrate that degradation inhibition enhances PDGFRa release through EVs. . The loading controls are indicated, and the molecular weights are expressed in kilodaltons. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: CD81, cluster of differentiation 81; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NS, not significant; TfR, transferrin receptor.
TYROSINE 720 PHOSPHORYLATION IS ESSENTIAL FOR PDGFRa RELEASE THROUGH EVs
Tyrosine phosphorylation and lysine ubiquitination on RTKs are essential for downstream signaling and for receptor internalization and degradation. (24) (25) (26) (27) Based on our results, we next sought to explore posttranslational modifications that specifically drive PDGFRa enrichment in EVs. For this purpose, ubiquitin and phospho-mutants were generated from a WT PDGFRa-FLAG plasmid containing a green fluorescent protein (GFP) reporter gene. Based on canonically important residues of PDGFRa from the literature, (9, 10, 28, 29) we generated lysine971-toarginine, tyrosines572/574-to-phenylalanines, and tyrosine720-to-phenylalanine (Y720F) mutants (Supporting Fig. S3 ). We specifically used LX2 cells for those studies, which express only low levels of endogenous PDGFRa. LX2 cells were first transfected with WT PDGFRa plasmid, and the overexpression was measured by GFP expression (Fig. 3A) , by PDGFRa mRNA levels (Fig. 3B, left) , and by WB in cells and EVs (Fig. 3B, right) . Next, LX2 cells were mock-transfected or transfected with WT or mutated PDGFRa. All mutants impaired PDGFRa downregulation in cell lysates after PDGF-BB treatment. However, only Y720F mutant consistently abolished PDGFRa enrichment in EVs (Fig. 3C) . As a control, WT or Y720F PDGFRa-transfected LX2 cells were treated with vehicle, TGFb, or lipopolysaccharide (LPS). Neither TGFb nor LPS induced WT or Y720F PDGFRa enrichment in EVs (Supporting Fig. S4A ), suggesting that phosphorylated Y720-dependent PDGFRa targeting to EVs is selectively induced by PDGF-BB. To confirm the importance of Y720 phosphorylation in PDGFRa release through EVs, we generated a constitutively active phosphomimetic Y720-to-glutamate (Y720E) mutation construct. LX2 cells were transfected with WT or Y720E PDGFRa and cultured in basal condition. WT and Y720E PDGFRa were overexpressed at the same level (Fig. 3D, bottom right) . Y720E construct induced PDGFRa enrichment in EVs, similarly to the PDGF-BB effect, and accumulation in cell lysate (Fig. 3D) . We next investigated whether impairment of Y720 phosphorylation enhances PDGFRa degradation by examining PDGFRa ubiquitination levels. LX2 cells were cotransfected with ubiquitin-hemagglutinin (HA) plasmid and with WT or Y720F PDGFRa plasmid. Cells were then treated for 0, 5, 10, or 30 minutes with PDGF-BB. PDGFRa was immunoprecipitated using anti-FLAG antibody, and ubiquitin levels of the receptor were assessed using anti-HA antibody. At all time points, Y720F mutant showed at least 2-fold more ubiquitination than WT PDGFRa (Fig. 3E, left) . Nevertheless, ubiquitination has been reported to be important both for degradation (30, 31) and for EV release. (32) Because p62 is implicated in protein degradation, we examined coimmunoprecipitation of p62 with PDGFRa. Indeed, p62-Y720F mutant association was enhanced compared to WT PDGFRa (Fig. 3E, right) , suggesting a higher degradation for the receptor with impaired Y720 phosphorylation. Taken together, these results suggest that Y720 phosphorylation is crucial for PDGFRa enrichment in EVs by preventing PDGFRa degradation. Furthermore, these data provide an association between degradation and secretion: impairment of degradation enhances PDGFRa release through EVs, and inhibition of PDGFRa enrichment in EVs induces its association to degradation molecules.
SHP2 ACTIVITY IS ESSENTIAL FOR PDGFRa EV SORTING
SHP2 binds specifically to the phosphorylated Y720 of PDGFRa (10, 33) and is essential for downstream signaling.
(34) Thus, we investigated the role of SHP2 in PDGFRa enrichment in EVs. We examined the binding of SHP2 to WT and Y720F PDGFRa. SHP2 binding to Y720F was decreased compared to WT PDGFRa (Fig. 4A) . We then inhibited SHP2 activity by pretreating human primary HSCs with an SHP2 selective inhibitor (SHP099) prior to LPS, TGFb, or PDGF-BB addition. Inhibition of SHP2 activity did not induce changes in cellular PDGFRa levels but significantly decreased PDGFRa enrichment in EVs under the PDGF-BB condition (Fig. 4B) . However, SHP099 did not block PDGFRa enrichment in EVs under TGFb or LPS stimulation (Supporting Fig.  S4B ). Next, we performed SHP2 silencing using siRNA transfection. SHP2 knockdown was confirmed by WB (Fig. 4C, top) , had no effect on the secreted EV number (Fig. 4C, NTA histogram) , and did not change the cellular levels of PDGFRa. However, SHP2 silencing significantly reduced PDGFRa targeting to EVs (Fig. 4D) , similar to SHP099. To further confirm the importance of SHP2, we investigated the role of its catalytic activity in PDGFRa enrichment in EVs using exogenous WT and a cysteine459-to-serine (C459S) mutant SHP2. (35) SHP2 overexpression was confirmed using a WB assay (Fig. 4E) . Congruent with the previous results, the impaired catalytic function (C459S SHP2 mutant) significantly abolished PDGFRa enrichment in EVs, in vehicle, and in PDGF-BB conditions, without affecting PDGFRa cellular levels (Fig. 4F) . Moreover, and in line with mass spectrometric screening results, SHP2 was also enriched in EVs derived from PDGF-BB-treated HSCs. This enrichment was abolished when the . (E) LX2 cells were transfected with ubiquitin-HA plasmid and with WT or Y720F PDGFRa-FLAG plasmid. Two days later, cells were treated with PDGF-BB as indicated. PDGFRa was immunoprecipitated using an anti-FLAG antibody. Ubiquitin was detected using an anti-HA antibody (left). Coimmunoprecipitation with p62 was also assessed by WB (right) (n 5 3). The loading controls are indicated, and the molecular weights are expressed in kilodaltons. *P < 0.05. Abbreviations: CD81, cluster of differentiation 81; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IP, immunoprecipitate; NS, not significant; P, PDGF-BB; Ub, ubiquitin; V, vehicle.
catalytic domain of SHP2 was impaired (C459S SHP2 mutant; Fig. 4F ). PDGFRa phosphorylation and SHP2 are important for extracellular signalregulated kinase 1/2 (Erk1/2) activation and downstream signaling. (25, 34) Thus, we examined Erk1/2 phosphorylation induced by Y720F mutant and after
FIG. 4. SHP2 activation promotes PDGFRa enrichment in HSC-derived EVs. (A) LX2 cells were transfected with WT or with Y720F
PDGFRa-FLAG plasmid for 2 days and then treated with PDGF-BB for 30 minutes. PDGFRa was immunoprecipitated using an anti-FLAG antibody. Coimmunoprecipitation of SHP2 was assessed by WB (n 5 3). (B) Primary human HSCs were treated with SHP099 for 1 hour. PDGF-BB was added, and cells were cultured for 12 additional hours. Whole-cell lysates and EVs were examined by WB (n 5 6). (C) HSCs were transfected with SHP2 siRNA, and 3 days later SHP2 knockdown efficiency in cells was examined by WB (n 5 3). (D) Two days after SHP2 siRNA transfection, HSCs were cultured with PDGF-BB for 12 hours. Whole-cell lysates and EVs were analyzed by WB (n 5 4). (E) LX2 cells were transfected with WT SHP2 construct, and 2 days later the overexpression was examined by WB (n 5 4). (F) LX2 cells were cotransfected with WT PDGFRa and WT or C459S SHP2 constructs for 2 days. Cells were then treated with vehicle or PDGF-BB for 12 additional hours. Whole-cell lysates and EVs were analyzed by WB (n 5 3). The loading controls are indicated, and the molecular weights are expressed in kilodaltons. *P < 0.05, ***P < 0.001. Abbreviations: CD81, cluster of differentiation 81; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IP, immunoprecipitate; NS, not significant. SHP2 inhibition. Y720F mutant decreased Erk1/2 activation upon PDGF-BB treatment (Supporting Fig. S4C ). In line with this, SHP2 inhibition using SHP099 compound and C459S SHP2 mutant abolished Erk1/2 phosphorylation (Supporting Fig. S4D,  E) . Finally, Erk1/2 inhibitor SCH772984 decreased PDGF-BB-induced PDGFRa enrichment in EVs and in cell lysates (Supporting Fig. S4F ). In summary, these data demonstrate that upon PDGF-BB, but not LPS or TGFb, treatment SHP2 binds to phosphorylated Y720 and SHP2 phosphatase activity induces PDGFRa and SHP2 enrichment in EVs. Moreover, Erk1/2 activation is also important for PDGFRa enrichment in EVs, demonstrating the crucial role of downstream signaling molecules in RTK trafficking through EVs.
PDGFRa-ENRICHED EVs PROMOTE HSC MIGRATION
PDGFRa is implicated in cell migration (1) ; thus, we tested whether PDGFRa enrichment in EVs induces HSC migration. LX2 cells overexpressing PDGFRa and LX2-derived EVs were used. To examine EV uptake, we incubated LX2 recipient cells with 2 3 10 9 EVs derived from MOCK or WT PDGFRatransfected LX2 donor cells for 3 hours. Recipient cells showed higher levels of PDGFRa when incubated with PDGFRa-overexpressing EVs than MOCKEVs (Fig. 5A) . Next, we performed a wound-healing assay to examine the role of PDGFRa-enriched EVs on LX2 migration. Recipient cells were incubated for 24 hours with EVs derived from either MOCK or WT PDGFRa-transfected cells, each treated with either vehicle or PDGF-BB. PDGFRa-EVs induced a greater migration of the recipient cells when compared to MOCK-EVs (Fig. 5B,C) . When either MOCK or PDGFRa-transfected donor cells were treated with PDGF-BB, EVs induced an even greater migration (Fig. 5B,C) . These results were confirmed by using primary human HSCs and HSC-derived EVs; EVs derived from PDGF-BB-treated HSCs induced greater migration than EVs derived from vehicletreated HSCs (Supporting Fig. S5A) . Furthermore, recipient cell migration was reduced when EVs were derived from SHP099-treated PDGFRa-overexpressing donor cells (Supporting Fig. S5B ). Despite the effect on migration, there was no stimulatory effect on aSMA, collagen 1, or fibronectin mRNA levels in recipient cells when EVs were enriched for PDGFRa (Supporting Fig. S6A ). The effect of these EVs was also examined on liver macrophages and their canonical functions such as tumor necrosis factor alpha and interleukin-1b mRNA induction. PDGFRa-enriched EVs did not increase tumor necrosis factor alpha or interleukin-1b mRNA levels in Kupffer cells (Supporting Fig. S6B ), suggesting that their effect might be selective to HSC migration. To examine how the transfer of PDGFRa through EVs triggers migration in recipient cells, a phospho-kinase protein array was performed on these EVs. Indeed, PDGFRaoverexpressing EVs had higher levels of promigration proteins such as phospho-focal adhesion kinase and phospho-protein kinase B 1/2/3 (Supporting Fig.  S7A-C) . TGFb did not induce an increase of PDGFRa signaling in the EVs (Supporting Fig.  S7D ). In summary, these results demonstrate that PDGF-BB-dependent PDGFRa-enriched EVs principally promote HSC migration, likely by transferring activated downstream signaling molecules, critical for these processes.
PDGFRa-ENRICHED EVs PROMOTE LIVER FIBROSIS
Based on the in vitro results and because HSC migration contributes to liver fibrosis in vivo, we next examined the effect of PDGFRa-enriched EVs in liver fibrosis. For this purpose, uptake of injected EVs to the liver was first assessed. PDGFRa-FLAG-EVs were labeled with the green fluorescent membrane dye PKH67 and injected into the tail vein. Mice were sacrificed 5 hours later. Compared to saline-injected mice, EV-injected mice showed great numbers of fluorescent green puncta in their livers (Supporting Fig. S8A ). FLAG immunostaining confirmed the presence of EVs in the liver after intravenous as well as intraperitoneal injection (Supporting Fig. S8B ). Based on the above, 2 3 10 9 EVs, derived from MOCK-transfected or PDGFRa-transfected LX2 cells, were transplanted daily by intraperitoneal injections in olive oil or CCl 4 -treated mice for 4 weeks. Interestingly, PDGFRa-EVs induced a significant increase by sirius red staining in the olive oil and CCl 4 groups (Fig. 5D) . Moreover, PDGFRa-EV transplant significantly enhanced levels of profibrotic proteins PDGFRa, PDGFRb, aSMA, and collagen 1 in whole-liver lysates, as shown by the quantification of WB bands (Fig. 5E) . The in vivo profibrogenic role of PDGFRa-enriched EVs was confirmed in a BDL-induced fibrosis model. PDGFRa-EVs, but not MOCK-EVs, significantly enhanced BDL-induced liver fibrosis, as demonstrated 4 injections. Livers were analyzed by sirius red (D) and WB (E) (n 5 5-9 animals/group). The loading controls are indicated, and the molecular weights are expressed in kilodaltons. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars, 50 lm. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PBS, phosphate-buffered saline.
by sirius red staining and protein levels of collagen 1 and aSMA (Supporting Fig. S9 ). In summary, these results demonstrate that PDGFRa-enriched EVs potentiate liver fibrosis in vivo in response to injury.
SHP2 INHIBITION REDUCES PDGFRa RELEASE THROUGH EVs AND PREVENTS LIVER FIBROSIS IN VIVO
As PDGFRa-enriched EVs are profibrogenic, we hypothesized that inhibition of PDGFRa release through EVs may reduce liver fibrosis. Based on the in vitro effect of SHP2 inhibition on PDGFRa enrichment in EVs, we examined the in vivo effect of SHP099 on PDGFRa release through EVs. Mice were treated with olive oil, CCl 4 , or CCl 4 1SHP099 for 4 weeks. As expected, CCl 4 induced an increase in PDGFRa enrichment in serum EVs (Fig. 6A) , similar to the BDL model (Fig. 1D) . Importantly, SHP099 administration abolished this enrichment (Fig. 6A) , confirming our in vitro results (Fig. 4B) . Interestingly, SHP099 also significantly abolished liver fibrosis as shown by aSMA and collagen 1 protein levels and by sirius red and Masson's trichrome staining (Fig. 6B,C) . These results were also confirmed in a BDL model, where SHP099 reduced sirius red staining and collagen 1 protein levels in whole-liver lysates (Supporting Fig.  S10 ). To further support the role of SHP2 in PDGFRa enrichment in EVs and liver fibrosis, mice were treated with olive oil, CCl 4 , CCl 4 1PDGFRa-EVs, or CCl 4 1 PDGFRa-SHP099-EVs.
PDGFRa-SHP099-EVs were derived from PDGFRa-overexpressing donor cells treated with SHP099. Sirius red staining was higher in CCl 4 1PDGFRa-EV-injected mice than in CCl 4 -injected mice. This increase was attenuated when PDGFRa-SHP099-EVs were administered (Supporting Fig. S11A,B) . This was confirmed by collagen 1 and aSMA WB (Supporting Fig. S11C) . In another experiment, we investigated the role of EVs derived from sera of olive oil-treated, CCl 4 -treated, or CCl 4 1SHP099-treated donor mice in recipient WT mice. Sirius red staining of recipient mouse livers did not display any difference between the three groups (Supporting Fig. S11D ), suggesting that EVs require a chronic liver injury stimulus such as CCl 4 in order to manifest fibrosis. In summary, these results support the role of SHP2 in PDGFRa enrichment in EVs, which drive liver fibrosis.
Discussion
In this study, we unveil a pathway of broad biological relevance involving the targeting of PDGFRa to EVs and their role in liver fibrosis. We demonstrate that PDGFRa enrichment in HSC-derived EVs is a mechanism to regulate PDGFRa cellular levels upon ligand binding, in close association with its degradation. Phosphorylation of tyrosine 720 drives PDGFRa targeting to EVs but not to degradation by binding to SHP2, suggesting a different role for this signaling molecule. Furthermore and most importantly, we provide evidence that PDGFRa-enriched EVs trigger in vitro HSC migration and in vivo liver fibrosis, which can be therapeutically targeted by inhibition of SHP2 (Fig. 7) .
EVs have emerged as an important mechanism for cell-to-cell communication by transporting, among several types of molecules, functional RTKs such as epidermal growth factor receptor. (13, 36, 37) In liver disease, hepatocyte-derived or endothelial cell-derived EVs participate in disease progression. (18, 19) Nevertheless, little is known about EVs deriving from HSCs, the main mediators of liver fibrosis. In this study, we demonstrate that HSC-derived EVs transport PDGFRa, which is enriched in the EVs upon PDGF-BB stimulation, suggesting a regulation mechanism for its trafficking, in addition to its degradation. Some prior studies show that degradation inhibition by bafilomycin A1 enhances EV release. (38, 39) In addition to this, here we demonstrate that degradation inhibition leads to further enrichment of EVs for PDGFRa and, in turn, blockage of PDGFRa enrichment in EVs enhances its degradation. This close relation between degradation and release through EVs suggests a fine-tuned regulation of the bioavailability of PDGFRa in response to ligand stimulation.
It has been reported that PDGFRa can be secreted through oligodendrocyte-derived EVs during development. (40) However, the mechanism of PDGFRa release through EVs, and of RTKs in general, remains unknown. Some studies demonstrate that association to RalA and RalB proteins (41) or posttranslational modifications such as ISGylation (39) and ubiquitination (32) are essential for general EV secretion. However, ubiquitination is also crucial for cargo degradation. Therefore, the precise mechanism targeting PDGFRa to EVs rather than to degradation and whether ubiquitin is involved in this decision remain unclear. Some prior studies indicate a link between phosphorylation of proteins and their release through EVs, (42, 43) but little is known about the balance between phosphorylation and ubiquitination in the fate of RTK trafficking. To understand the role of posttranslational modifications in PDGFRa trafficking to EVs, we studied several phospho-mutants and ubiquitination mutants. Only impaired tyrosine720 phosphorylation (Y720F) FIG. 6 . In vivo SHP2 inhibition reduces PDGFRa release through serum EVs and prevents liver fibrosis. C57Bl/6 male and female mice were treated for 4 weeks with olive oil, CCl 4 , or CCl 4 1SHP099. Serum EVs (A) and whole-liver lysates (B) were analyzed by WB. Liver sections were examined by sirius red staining and Masson's trichrome staining (C). The loading controls are indicated, and the molecular weights are expressed in kilodaltons. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars, 50 lm; n 5 5-10 animals/group.
abolished PDGFRa enrichment in EVs. Moreover, Y720F mutation enhanced PDGFRa ubiquitination and its association with the autophagic protein p62. These data demonstrate that PDGFRa enrichment in EVs is dependent on Y720 phosphorylation and that impairment of this phosphorylation redirect PDGFRa toward degradation by elevating its ubiquitination levels. This suggests that specific tyrosine residues have distinct roles regarding the fate of the receptor, which can be important for downstream signaling. The specific partner binding to phosphorylated Y720 is SHP2, (10) which is an essential phosphatase for the activation of downstream signaling of RTKs. (35) SHP2 has been reported to promote breast cancer and liver cancer progression by triggering several biological processes such as cell proliferation and migration. (44, 45) Interestingly, a recent study emphasizes the role of phosphatases in cellular trafficking and rerouting of RTKs. (46) In our study, SHP2 promoted PDGFRa trafficking through EVs. Moreover, our proteomics analysis demonstrated that SHP2 is also enriched in EVs after PDGF-BB stimulation. SHP2 can modulate mitogen-activated protein kinase activity such as Erk1/2. (34, 35) Furthermore, mitogen-activated protein kinase molecules KRAS-mitogen-activated protein kinase kinase control the sorting of Ago2 protein into EVs. (42) Along this line, we show that inhibition of Erk1/2 activation abolishes PDGFRa enrichment in EVs. Taken together, these results demonstrate that SHP2 binding to PDGFRa is essential for enrichment of these two proteins in EVs, which suggests a potential role of these EVs in liver fibrosis.
RTKs, such as epidermal growth factor receptor, can be transported through EVs and trigger signaling in recipient cells. (36, 47) Moreover, HSC-derived EVs can bind to other HSCs through integrins and heparin sulfate proteoglycans. (48) Congruently, we demonstrate that PDGFRa trafficking through HSC-derived EVs promotes in vitro HSC migration. Nevertheless, much less is known about the in vivo role of HSC-derived EVs. In our study, ALD patients and mice with BDL contained higher levels of PDGFRa in their serum EVs compared to respective controls. Moreover, we demonstrate that PDGFRa-enriched EVs induced in vivo liver fibrosis, emphasizing a mechanism involved in hepatic fibrosis. Finally, in vivo inhibition of PDGFRa release through EVs using a specific SHP2 inhibitor in a CCl 4 -induced fibrosis model correlated with significant reduction of liver fibrogenesis, providing a potential therapeutic strategy for liver diseases.
In conclusion, our study demonstrates a SHP2-dependent mechanism by which PDGFRa enrichment in HSC-derived EVs drives liver fibrosis. Inhibition of PDGFRa enrichment in EVs may be a novel therapeutic strategy against liver diseases.
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